|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||146.55 - 149.85|
|52 Week Range||109.31 - 174.04|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||2.28%|
|Beta (5Y Monthly)||0.91|
|Expense Ratio (net)||0.46%|
BlackRock, Inc. (NYSE: BLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup.
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.
Shares of Enveric Biosciences Inc. doubled in very heavy volume in midday trading Wednesday, after the Florida-based biotechnology company focused on cannabinoid-based treatments and cancer treatments said it acquired a perpetual license from Diverse Biotech for novel molecules for developing cancer treatments. Trading volume ballooned to 214.6 million shares, compared with the full-day average of about 2.4 million shares over the past 30 days. Enveric's stock, which was up 100%, was both the biggest gainer and most actively traded on major U.S. exchanges. "This is an exclusive, novel way of bringing together CBD and well-known, existing compounds that hold promise to create a new, improved drug class," added Enveric Chief Executive David Johnson. "As a patient-centric company, Enveric is constantly looking for new ways to eliminate or minimize cancer treatment side effects for patients in need." Enveric's stock has still lost 7.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 1.7% and the S&P 500 has gained 6.3%.